Ribociclib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ribociclib: From HR+/HER2- Metastatic Breast Cancer to Myeloid Leukemia
One-Sentence Summary
Ribociclib (DrugBank DB11730) is a CDK4/6 inhibitor whose established clinical use — evident throughout the literature in this evidence pack — is HR+/HER2-negative advanced/metastatic breast cancer; no formal original-indication record exists in the Danish regulatory file because the drug is currently not marketed in Denmark. The TxGNN model’s top-ranked prediction is Myeloid Leukemia, supported by only 0 clinical trials and 3 publications, two of which describe a case report of AML arising after CDK4/6-inhibitor treatment rather than evidence of therapeutic benefit. Evidence is weak and directionally ambiguous — this candidate is not ready to advance.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in the Danish regulatory record (drug unmarketed); literature in this pack consistently identifies HR+/HER2- metastatic breast cancer as the established use |
| Predicted New Indication | Myeloid Leukemia |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L4 |
| Denmark Market Status | Not marketed (未上市) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is flagged as a data gap in the formal record. Based on the literature retrieved in this pack, ribociclib is an orally administered, highly selective CDK4/6 inhibitor that blocks the CDK4/6–Rb pathway, arresting the cell cycle at the G1/S checkpoint. This mechanism underlies its established efficacy in HR+/HER2-negative breast cancer, where blocking proliferation of hormone-driven tumor cells is the therapeutic goal.
The mechanistic case for myeloid leukemia is genuinely mixed. One in-vitro study (PMID 32560251) explores CDK4/6 inhibitors as a way to overcome pharmacokinetic drug resistance in acute myeloid leukemia (AML) cells, offering a plausible rationale for anti-leukemic activity. However, a second report (PMID 30575100) describes a patient who developed AML with eosinophilia after CDK4/6-inhibitor treatment, in a setting of underlying clonal hematopoiesis — i.e., the drug class as a possible contributor to, rather than treatment for, myeloid malignancy. A third publication (PMID 41641105) is an unrelated vulvar adenocarcinoma case report with no clear connection to myeloid leukemia.
Because the supporting evidence points in two opposite directions — potential anti-leukemic mechanism vs. a signal of treatment-emergent AML — and no clinical trial has directly tested ribociclib in myeloid leukemia, the mechanistic plausibility cannot be considered established. This is reflected in the L4/S0 evidence classification and “Hold” recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32560251 | 2020 | Preclinical/mechanistic (in vitro) | Cancers | Explores CDK4/6 inhibitors to overcome pharmacokinetic drug resistance in AML cells, associated with ABCB1/ABCG2 transporter overexpression |
| 30575100 | 2019 | Case report (adverse event) | American Journal of Hematology | AML with eosinophilia arising after CDK4/6-inhibitor treatment, in a patient with underlying clonal hematopoiesis of indeterminate potential — a treatment-related risk signal, not a treatment benefit |
| 41641105 | 2026 | Case report (low relevance) | Frontiers in Oncology | Describes a vulvar/breast dual-primary adenocarcinoma case; no substantive link to myeloid leukemia |
Denmark Market Information
Ribociclib currently has no marketing authorisation on file in the Danish regulatory record (market status: 未上市 / not marketed; total authorisations: 0). No product name, dosage form, or approved indication text is available to report.
Cytotoxicity
Ribociclib is an antineoplastic agent (oral CDK4/6 inhibitor used in oncology), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) — not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | High — literature in this pack consistently reports neutropenia, thrombocytopenia, anemia, lymphopenia, and febrile neutropenia as class-level hematological toxicities of CDK4/6 inhibitors |
| Emetogenicity Classification | Low to moderate (consistent with other CDK4/6 inhibitors) |
| Monitoring Items | CBC with differential, liver function tests, ECG/QTc (QT prolongation has been reported for this class) |
| Handling Protection | Please refer to the Summary of Product Characteristics (SmPC) and institutional hazardous-oral-oncolytic handling policy — formal handling classification data is not available in this evidence pack |
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in the regulatory record for this candidate (data gap DG001, Blocking severity).
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence for the myeloid leukemia prediction is L4 (mechanistic/case-report only), with zero clinical trials and directionally conflicting literature — one mechanistic study suggests possible anti-leukemic activity, while a case report suggests the drug class may instead cause treatment-related AML. Combined with the drug’s unmarketed status in Denmark and Blocking-severity gaps in safety labeling and MOA documentation, there is insufficient basis to proceed.
To proceed, the following is needed:
- Danish/EU SmPC with formal warnings, contraindications, and DDI data (DG001, Blocking)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent (DG002, High)
- A dedicated preclinical or early-phase clinical study directly testing ribociclib activity in myeloid leukemia, rather than relying on incidental case reports
- Clarification of whether the AML signal in PMID 30575100 represents a class effect, requiring pharmacovigilance follow-up before any repurposing pathway is considered
- Formal confirmation of Denmark marketing status before any local development pathway is scoped
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.